Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice
King, R. G.; Silva-Sanchez, A.; Peel, J. N.; Botta, D.; Meza-Perez, S.; Allie, R.; Schultz, M. D.; Liu, M.; Bradley, J. E.; Qiu, S.; Yang, G.; Zhou, F.; Zumaquero, E.; Simpler, T. S.; Mousseau, B.; Killian, J. T.; Dean, B.; Shang, Q.; Tipper, J. L.; Risley, C.; Harrod, K. S.; Feng, R.; Lee, Y.; Shiberu, B.; Krishnan, V.; Peguillet, I.; Zhang, J.; Green, T.; Randall, T. D.; Georges, B.; Lund, F. E.; Roberts, S.
Show abstract
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective preventive vaccination to reduce burden and spread of severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) in humans. Intranasal vaccination is an attractive strategy to prevent COVID-19 as the nasal mucosa represents the first-line barrier to SARS-CoV-2 entry before viral spread to the lung. Although SARS-CoV-2 vaccine development is rapidly progressing, the current intramuscular vaccines are designed to elicit systemic immunity without conferring mucosal immunity. Here, we show that AdCOVID, an intranasal adenovirus type 5 (Ad5)-vectored vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, elicits a strong and focused immune response against RBD through the induction of mucosal IgA, serum neutralizing antibodies and CD4+ and CD8+ T cells with a Th1-like cytokine expression profile. Therefore, AdCOVID, which promotes concomitant systemic and local mucosal immunity, represents a promising COVID-19 vaccine candidate.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta 97%
- Polymeric Pathogen-like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A Virus 96%
- Memory B cell and humoral responses elicited by Sputnik V in naïve and COVID-19-recovered vaccine recipients 95%
Similar papers in this journal
- Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice 95%
- Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern 94%
- VSA-2, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine 94%
Similar papers in this journal
- SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses 94%
- Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses 94%
- A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses 93%
Similar papers in this journal
- SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern 96%
- Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms 95%
- Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial 93%
Similar papers in this journal
- Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity 96%
- BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine 96%
- Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.